Advanced glycation end product concentrations in follicular fluid of women undergoing IVF/ICSI with a GnRH agonist protocol. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Yao, Qi; Liang, Yuanjiao; Shao, Yong; Bian, Wenwen; Fu, Haiyan; Xu, Juanjuan; Sui, Liucai; Yao, Bing; Li, Meiling
• Is Part Of: Reproductive biomedicine online. Volume 36:Issue 1(2018)
• Page Start: 20
• Page End: 25
• Publication Date: 2018-01
• Subjects: Advanced glycation end products -- Embryo quality -- Follicular fluid -- IVF/ICSI -- Ovarian responsiveness; Human reproductive technology -- Periodicals; Human embryo -- Periodicals; Reproduction -- Periodicals; 616.692
• DOI: 10.1016/j.rbmo.2017.09.003
• Languages: English
• ISSNs: 1472-6483

Abstract

Abstract: The accumulation of advanced glycation end products (AGE) is associated with ovarian dysfunction. This study examines whether the accumulation of AGE in follicular fluid affects ovarian responsiveness and embryo quality during IVF/intracytoplasmic sperm injection (IVF/ICSI) with a gonadotrophin-releasing hormone (GnRH) agonist protocol. The levels of AGE in follicular fluid were measured in 127 women undergoing IVF/ICSI in GnRH agonist cycles. Plasma hormones were also measured. Embryos were graded using standard approaches. There were inverse associations between follicular fluid AGE concentration and number of oocytes retrieved, number of fertilized oocytes, number of high-quality embryos, fertilization rate and high-quality embryo rate, adjusted for potential confounders. AGE concentration in follicular fluid was significantly higher in women with an ovarian response below the target (<7 oocytes) compared with those reaching the target (7–15 oocytes) or above the target (>15 oocytes). The cut-off value of 15.3 µg/ml for follicular fluid AGE showed 84.6% sensitivity and 55.5% specificity in evaluating the response to ovarian stimulation as below the target. The results suggest that ovarian responsiveness and embryo quality are related to intraovarian exposure to AGE.